Table 1.
Demographic Information of the 4 Trial Groups
| Characteristic | 200 µg Pr + MF59 | 200 µg Pr + AS01B | 40 µg Pr + AS01B | Placebo | Total |
|---|---|---|---|---|---|
| (n = 50) | (n = 50) | (n = 50) | (n = 10) | (n = 160) | |
| Age, y | |||||
| Median (IQR) | 24 (21–26) | 23.5 (21–28) | 25.5 (22–30) | 24 (22–30) | 24 (21–29) |
| 18–20 | 9 (18) | 9 (18) | 6 (12) | 2 (20) | 26 (16) |
| 21–30 | 30 (60) | 32 (64) | 32 (64) | 6 (60) | 100 (63) |
| 31–40 | 11 (22) | 9 (18) | 12 (24) | 2 (20) | 34 (21) |
| Sex | |||||
| Male | 19 (38) | 20 (40) | 25 (50) | 8 (80) | 72 (45) |
| Female | 31 (62) | 30 (60) | 25 (50) | 2 (20) | 88 (55) |
| Body mass index, kg/m2, median (IQR) | 22.6 (21–24) | 22.3 (21–26) | 22 (22–26) | 23 (21–26) | 22.8 (21–26) |
| Ethnicity | |||||
| Hispanic or Latino/a | 2 (4) | 1 (2) | 1 (2) | 1 (10) | 5 (3) |
| Not Hispanic or Latino/a | 48 (96) | 49 (98) | 49 (98) | 9 (90) | 155 (97) |
| Race | |||||
| United States, Asian | 1 (2) | 0 (0) | 1 (2) | 0 (0) | 2 (1) |
| United States, Black | 0 (0) | 1 (2) | 1 (2) | 1 (10) | 3 (2) |
| United States, White | 18 (36) | 16 (32) | 17 (34) | 3 (30) | 54 (34) |
| SSA, Black | 30 (60) | 30 (60) | 30 (60) | 6 (60) | 96 (60) |
| Mixed | 1 (2) | 3 (6) | 1 (2) | 0 (0) | 5 (3) |
| Vaccination frequencies | |||||
| Day 0 | 50 (100) | 50 (100) | 50 (100) | 10 (100) | 160 (100) |
| Day 28 | 49 (98) | 49 (98) | 50 (100) | 9 (90) | 157 (98) |
| Day 84 | 49 (98) | 49 (98) | 49 (98) | 9 (90) | 156 (98) |
| Day 168 | 49 (98) | 48 (96) | 48 (96) | 9 (90) | 154 (96) |
Data are No. (%) except where indicated.
Abbreviations: IQR, interquartile range; Pr, protein; SSA, sub-Saharan Africa.